Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

690 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W. Girard N, et al. Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20. Eur Respir J. 2012. PMID: 21778168
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M. Cortes-Funes H, et al. Ann Oncol. 2005 Jul;16(7):1081-6. doi: 10.1093/annonc/mdi221. Epub 2005 Apr 25. Ann Oncol. 2005. PMID: 15851406
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ. Rosell R, et al. Lung Cancer. 2005 Oct;50(1):25-33. doi: 10.1016/j.lungcan.2005.05.017. Lung Cancer. 2005. PMID: 16011858
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T. Taron M, et al. Clin Cancer Res. 2005 Aug 15;11(16):5878-85. doi: 10.1158/1078-0432.CCR-04-2618. Clin Cancer Res. 2005. PMID: 16115929
Future directions in the second-line treatment of non-small cell lung cancer.
Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart N, Jablons D. Rosell R, et al. Semin Oncol. 2006 Feb;33(1 Suppl 1):S45-51. doi: 10.1053/j.seminoncol.2005.12.002. Semin Oncol. 2006. PMID: 16472709 Review.
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castellà E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomàs M, Mate JL, Moran T, Rosell R. Molina-Vila MA, et al. J Thorac Oncol. 2008 Nov;3(11):1224-35. doi: 10.1097/JTO.0b013e318189f579. J Thorac Oncol. 2008. PMID: 18978556
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.
Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjós M, Castellà E, Moran T, Bertran-Alamillo J, Mayo-de-Las-Casas C, Queralt C, Rosell R. Garcia-Olivé I, et al. Eur Respir J. 2010 Feb;35(2):391-5. doi: 10.1183/09031936.00028109. Epub 2009 Jul 30. Eur Respir J. 2010. PMID: 19643949
690 results
Jump to page
Feedback